M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market BioSpaceCatalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.Rare DiseaseRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) BioSpace Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bayer plans filings for cardiac amyloidosis imaging agentNext: Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
